In the article titled "The Effect of a Hydrolyzed Polysaccharide Dietary Supplement on Biomarkers in Adults with Nonalcoholic Fatty Liver Disease" \[1\], the Morisky Medication Adherence Scale (MMAS) was used without proper permission from Dr. Donald E. Morisky, the creator of the scale. The authors replicated the study without using MMAS. The revised article is as follows.

1. Introduction {#sec1}
===============

Nonalcoholic fatty liver disease (NAFLD) describes a spectrum of diseases characterized by hepatic fat accumulation \[1\]. NAFLD ranges from simple steatosis to non-alcoholic steatohepatitis (NASH) categorized with inflammation, fibrosis, and cirrhosis \[2\]. Approximately, 20--30% of the population has NAFLD \[3, 4\], while the prevalence of NASH is roughly 2-3% \[4, 5\]. NAFLD has risen in prevalence in proportion to obesity, type 2 diabetes, and dyslipidemia \[2\], and NAFLD is an emerging epidemic. The goal of NAFLD management is to improve steatosis and prevent fibrosis. Currently, this is accomplished via lifestyle interventions, medical treatments, alternative therapies, and surgery aimed at modifying key NAFLD risk factors: obesity and insulin resistance \[1, 6--8\].

Nutritional optimization through dietary supplementation may offer an alternative treatment strategy for NAFLD. Many studies have shown that a potent hydrolyzed polysaccharide, Rice Bran Arabinoxylan Compound (RBAC), possesses a biologic response modifier effect on immune system function, particularly natural killer (NK) cell activity \[9--15\]. For example, two separate rat studies have demonstrated the effectiveness of RBAC on various biomarkers after d-galactosamine- (Ga1N-) induced acute liver disease, which is essentially a model of hepatitis in humans \[9, 10\]. This form of hepatitis was shown to be suppressed by RBAC. The protective mechanism was mediated in part by downregulation of interleukin-18 (IL-18) in the first study \[9\]. The second study showed that nuclear factor-*κ*B (NF-*κ*B) and CD14+ were involved in the suppressive action of RBAC on GalN-induced hepatitis \[10\]. The serum activity of transaminases (alanine transaminase \[ALT\] and aspartate transaminase \[AST\]) was significantly higher after GalN treatment, but the changes were attenuated by RBAC. Furthermore, GalN-induced inhibitor of *κ*B kinase degradation appeared to be prevented by RBAC, and associated suppression of NF-*κ*B activation was noted. Additionally, RBAC significantly inhibited CD14+ mRNA expression \[10\]. RBAC is also likely to possess antioxidant capabilities, as it has been shown to enhance macrophage phagocytic activity and nitric oxide release and scavenge free radicals in a dose-dependent manner \[11, 12\]. RBAC has been shown to have significant immunomodulatory and net anti-inflammatory activity in several studies, particularly in cancer \[13, 14\]. In our lab, we previously showed that RBAC enhanced NK cell cytotoxicity, demonstrated changes in 9 out of 12 cytokines and growth factors, and was well-tolerated and safe among a sample of healthy adults \[15\].

Based on the prior studies, dietary supplementation in NAFLD may confer favorable metabolic and immunological effects, yet we are aware of no study that has investigated the effect of a polysaccharide nutritional supplement like RBAC on related biomarkers in patients with this disease. The purpose of this study is to determine the effect of 90 days of RBAC treatment on biomarkers in patients with NAFLD.

2. Materials and Methods {#sec2}
========================

2.1. Subjects {#sec2.1}
-------------

The study was conducted with the approval of the University of Miami Institutional Review Board for human subject research (registry name: <http://www.clinicaltrials.gov>; registry number: [NCT02568787](https://www.clinicaltrials.gov/ct2/show/NCT02568787)). Potential subjects were initially identified from physician referrals, the Medical Wellness Center, and the Departments of Psychiatry and Behavioral Sciences and Medicine at the University of Miami Miller School of Medicine, where the data were collected. Recruitment began in June 2016 and ended in February 2017 after target enrollment was achieved. Inclusion criteria were as follows: (a) age 18 or older; (b) confirmed NAFLD diagnosis by referring or treating physician; (c) stable medication regimen during the intervention; (d) planning to maintain current medication during the course of the intervention; (e) previous dietary supplement usage of similar polysaccharide formulas permitted, but must be discontinued 2 weeks before and for the duration of the trial; (f) willing to follow recommendations for assessment and intervention study protocol; and (g) able to provide informed consent. Exclusion criteria were as follows: (a) currently enrolled in another research trial for similar investigative nutritional therapies; (b) known allergy to rice, rice bran, or mushrooms or related food products; (c) any gastrointestinal disorders that could lead to uncertain absorption of the study supplement; (d) use of lipid-lowering agent 3 months prior to study enrollment; (e) current immunomodulator use; (f) active chemotherapy; (g) severe anemia or other medical condition that would preclude a safe blood draw; (h) bleeding disorder; or (i) active pregnancy or attempting conception.

Thirty-nine subjects were screened for inclusion and exclusion criteria. Thirteen were ineligible to participate in the study, and three were eligible, but did not enroll. Thus, twenty-three subjects met the criteria and were enrolled in the study after signing the informed consent and HIPAA privacy forms prior to study entry. The participants were assigned by study staff using a simple randomization procedure to one of two conditions: (a) RBAC (*n* = 12) or (b) placebo (*n* = 11), using a random permutations table created by the principal investigator (JEL). All subjects and investigators were blinded to the treatment condition and remained blinded until data analysis. Placebo and supplements were provided by Daiwa Health Development (Gardena, CA, USA) labeled as Protocol A and Protocol B. Only a staff member at Daiwa Health Development knew the assignment of treatment to Protocol A or B. After randomization, participants were scheduled for assessments at baseline and 45 and 90 days of follow-up (±1 week). Blood was drawn at each time point to assess the biological markers. Subjects were compensated \$50 for completing the assessment at each time point. Three participants dropped out of the study at 45 days, and thus 20 subjects completed the study. Data collection was completed in May 2017.

2.2. Intervention {#sec2.2}
-----------------

All subjects were instructed to take 2 capsules 1 time per day (1 g/day total) for the 90-day intervention period. Subjects were advised to not modify dietary or physical activity habits or prescription medication use. Subjects were also instructed not to consume any known immune-active pharmaceutical agents or any dietary supplements containing mushroom products for two weeks prior to having the baseline assessment and until the conclusion of the 90-day study period. Consuming RBAC is similar to rice bran and should be tolerated like other common foods. We are not aware of any documented side effects of RBAC, and our first study with this product reported no adverse events \[15\]. RBAC is a water-soluble extract of rice bran that has been hydrolyzed by an enzyme complex extracted from shiitake mushroom. In addition, RBAC contains microcrystalline cellulose, hypromellose, sucrose fatty acid ester, gellan gum, and potassium acetate. Each capsule contained 500 mg of RBAC. The placebo capsules were indistinguishable from the RBAC, but contained cellulose.

2.3. Outcomes and Assessments {#sec2.3}
-----------------------------

Each participant completed basic demographics and medical history questionnaire at baseline. Subjects were also asked to list their current medications and note any changes in type or amount during the course of the study. Criteria used to select the assessment instruments included (a) appropriateness for the population; (b) ease of administration and scoring; (c) experience administering these measures; and (d) employment of measures involving a multimethod (i.e., self-report and biological values) approach to enhance the validity of the overall assessment.

2.4. Blood Draw Procedures {#sec2.4}
--------------------------

Participants abstained from caffeine and alcohol consumption for 24 hours before testing, which was conducted in the postabsorptive state following an overnight (12-hour) fast. A sample of blood (60 mL) was drawn at each visit.

2.5. Kidney Function, Liver Enzymes, and Oxidative Stress Markers {#sec2.5}
-----------------------------------------------------------------

Bilirubin, creatinine, protein, albumin, liver enzymes (AST, ALT, and alkaline phosphatase \[ALP\]), AST/ALT ratio, 4-hydroxynonenal, malondialdehyde, and *γ*-glutamyl transferase (GGT) were assessed at each time point.

2.6. Lipids {#sec2.6}
-----------

Total, low-density lipoprotein (LDL), very low-density lipoprotein (VLDL), and high-density lipoprotein (HDL) cholesterol and triglycerides were assessed at each time point.

2.7. Complete Blood Count {#sec2.7}
-------------------------

The standard complete blood count (CBC) was measured at each time point. Neutrophil-to-lymphocyte ratio (NLR; absolute count) was calculated as a marker that is predictive of chronic inflammation in cardiovascular disease and cancer and may be useful in evaluating disease status in NAFLD as well \[16--18\].

2.8. Immunological Variables {#sec2.8}
----------------------------

Proinflammatory cytokines (tumor necrosis factor \[TNF\]-*α*, TNF-*β*, interleukin \[IL\]-1*α*, IL-1*β*, IL-6, TNF RI, and IL-18), T helper (Th)-1 cytokines (interferon \[IFN\]-*γ*, IL-12, IL-2, IL-15, and TNF RII) and IL-8 and Th-2, Th-17, and anti-inflammatory cytokines (IL-4, IL-5, IL-17, IL-23, IL-10, and IL-13) were measured at each assessment.

2.9. Biomarker Assays {#sec2.9}
---------------------

Blood samples were collected into ethylene diamine tetra acetic acid (EDTA) anticoagulant tubes. Plasma was separated within 2 hours of collection and either analyzed on the same day (routine chemistries) or stored at −80°C until assayed (cytokines and oxidative stress markers). Routine chemistries, including bilirubin, creatinine, protein, albumin, AST, ALT, ALP, GGT, and all lipids, were measured on a Roche 6000 chemistry analyzer (Roche Diagnostics, Indianapolis, IN, USA) using manufacturers reagents and following all instructions for instrument set up and assay procedures. All chemistry tests had inter- and intra assay CVs \<4.5%. CBC was measured in whole blood on the day of collection using a Beckman Coulter UniCel DxH 600 hematology analyzer. Malondialdehyde and 4-hydroxynonenal were measured by ELISA using kits obtained from Cell Biolabs, Inc. (San Diego, CA, USA). Samples for malondialdehyde and 4-hydroxynonenal were frozen at −80°C until assayed, and all samples were analyzed on the same day.

The cytokines and growth factors were measured in plasma using Quansys reagents and ELISA kits (Quansys Biosciences, Logan, UT, USA) in the same way as reported previously \[19\]. The ranges of the cytokine and growth factor concentrations used in the standard calibration samples were adjusted for each analyte along with sample exposure time.

2.10. Descriptive and Control Variables {#sec2.10}
---------------------------------------

Demographics such as age, race/ethnicity, socioeconomic status, education, employment status, and current living situation were assessed at baseline. Medical history was measured with a questionnaire that included history of surgery, hospitalization, respiratory diseases, diabetes, coronary artery disease, neurodegenerative disorders, mental health, cancer, use of prescription and over-the-counter medications, and alcohol and tobacco consumption.

2.11. Adverse Events {#sec2.11}
--------------------

Participants were monitored until the end of the study. Potential side effects were explained to each participant during informed consent.

2.12. Statistical Analyses {#sec2.12}
--------------------------

Frequency and descriptive statistics were calculated on all variables. Independent samples *t*-tests and chi-squares were utilized to evaluate differences in sociodemographic and clinical history characteristics between groups at baseline. Percent change was calculated for the difference between (a) baseline and 45 days follow-up, (b) baseline and 90 days follow-up, and (c) 45 and 90 days follow-up for all biomarkers. Then, the percent change dependent variables were evaluated in one-way analysis of variance to compare differences between the placebo and RBAC groups. IBM SPSS Statistics 24 for Windows (IBM, Inc., Chicago, IL, USA) was used for statistical analyses, and *α* \< 0.05 was considered statistically significant.

3. Results {#sec3}
==========

3.1. Sociodemographics, Co-Morbid Disorders, and Medication Use {#sec3.1}
---------------------------------------------------------------

See [Table 1](#tab1){ref-type="table"} for the descriptive information of the sample for age, gender, race/ethnicity, education, and marital status, which were all nonsignificantly different between the RBAC and placebo groups. The most prevalent co-morbid conditions were hypertension (*n* = 11 \[48%\]), dyslipidemia (*n* = 11 \[48%\]), hypertriglyceridemia (*n* = 9 \[39%\]), and migraines (*n* = 6 \[26%\]), and the differences between groups for these disorders were insignificant. Subjects were taking an average of 4.1 prescription (SD = 4.3, *R* = 0, 17) and 1.3 over-the-counter (SD = 1.2, *R* = 0, 4) medications.

3.2. Analysis of Liver Enzymes, Kidney Function, Lipids, and Oxidative Stress Markers {#sec3.2}
-------------------------------------------------------------------------------------

During the entire study period, no adverse event was reported. [Table 2](#tab2){ref-type="table"} shows the descriptive statistics for liver enzymes, AST/ALT ratio, GGT, albumin, non-HDL cholesterol, and 4-hydroxynonenal. The percent change in ALP from baseline to 90 days was statistically significant (*F*\[1, 19\] = 5.1, *p* = 0.03), as the placebo group increased by 16.9% (SD = 19.7), while the RBAC group decreased by 3.1% (SD = 19.9). The percent change in ALP from baseline to 45 days was a statistical trend (*F*\[1, 19\] = 3.6, *p* = 0.07), as the placebo group increased by 9% (SD = 11.7), whereas the RBAC group decreased by 3.7% (SD = 16.9). The percent change in albumin from baseline to 90 days was a statistical trend (*F*\[1, 19\] = 3.1, *p* = 0.09), as the placebo group increased by 1.6% (SD = 3.0), whereas the RBAC group decreased by 1.0% (SD = 3.5). The percent change in AST/ALT ratio from 45 to 90 days was a statistical trend (*F*\[1, 19\] = 4.1, *p* = 0.06), as the placebo group increased by 14.2% (SD = 22.6), whereas the RBAC group decreased by 2.1% (SD = 13.2). Although not statistically significant, GGT decreased in the RBAC group from 67 IU/L at baseline to 47 IU/L at 90 days, while it increased in the placebo group from over 78 IU/L at baseline to 98 IL/L at 90 days. The percent change in the non-HDL cholesterol from baseline to 45 days was a statistical trend (*F*\[1, 19\] = 3.3, *p*=0.08), as the placebo group decreased by 5.8% (SD = 7.6), whereas the RBAC group increased by 5.3% (SD = 16.8). Although not statistically significant, 4-hydroxynonenal decreased in the RBAC group from baseline (121 *μ*g/mL) to 90 days (76 *μ*g/mL), whereas the placebo group increased from 145 *μ*g/mL at baseline to 911 *μ*g/mL at 90 days.

3.3. Analysis for While Blood Cell Subsets and Platelets {#sec3.3}
--------------------------------------------------------

[Table 3](#tab3){ref-type="table"} shows the descriptive statistics for white blood counts, neutrophils, lymphocytes, NLR, monocytes, eosinophils, and platelets. The percent change in white blood cells from baseline to 90 days was significantly different (*F*\[1, 19\] = 6.4, *p*=0.02), as the placebo group increased by 12.7% (SD = 9.8), whereas the RBAC group remained the same at 0.1% (SD = 12.0). The percent change in monocytes (%) from 45 to 90 days was significantly different (*F*\[1, 19\] = 5.9, *p*=0.02), as the placebo group decreased by 2.2% (SD = 18.7), whereas the RBAC group increased by 17.9% (SD = 18.3). The percent change in eosinophils (%) from baseline to 45 days was significantly different (*F*\[1, 19\] = 5.0, *p* = 0.03), as the placebo group decreased by 11.8% (SD = 39.8), whereas the RBAC group increased by 26.2% (SD = 36). The percent change in eosinophils (%) from baseline to 90 days was significantly different (*F*\[1, 19\] = 12.3, *p*=0.01), as the placebo group decreased by 12.7% (SD = 39.8), whereas the RBAC group increased by 30.6% (SD = 30.5). The percent change in total monocytes from 45 to 90 days was a statistical trend (*F*\[1, 19\] = 3.3, *p*=0.08), as the placebo group decreased by 0.2% (SD = 21.8), whereas the RBAC group increased by 18.7% (SD = 24.3). Although not statistically significant, neutrophils (%) decreased in the RBAC group from baseline (53.1) to 90 days (48.5), while no changed occurred in the placebo group from baseline (56.7) to 90 days (56.6). Additionally, the NLR decreased slightly in the RBAC group from baseline (1.5) to 90 days (1.4), whereas it remained constant at 1.8 from baseline to 90 days in the placebo group. The percent change in platelets (10^3^/*μ*L) from baseline to 90 days was significantly different (*F*\[1, 19\] = 5.7, *p* = 0.02), as the placebo group increased by 13.1% (SD = 21), whereas the RBAC group decreased by 5.1% (SD = 12.8). The percent change in platelets (10^3^/*μ*L) from baseline to 45 days was a statistical trend (*F*\[1, 19\] = 3.5, *p* = 0.07), as the placebo group increased by 6.1% (SD = 17.8), whereas the RBAC group decreased by 6.5% (SD = 12.4).

3.4. Analysis for Cytokines and Growth Factors {#sec3.4}
----------------------------------------------

[Table 4](#tab4){ref-type="table"} shows the descriptive statistics for the cytokines and growth factors. The percent change in IL-18 from 45 to 90 days was significantly different (*F*\[1, 19\] = 5.3, *p*=0.03), as the placebo group decreased by 22.9% (SD = 22.7), whereas the RBAC group increased by 29.1% (SD = 64). Although not statistically significant, IL-18 declined from 446 pg/mL at baseline to 221 pg/mL at 90 days for the RBAC group, whereas the placebo group slightly increased from baseline (256 pg/mL) to 90 days (263 pg/mL). The percent change in IL-6 from baseline to 45 days was a statistical trend (*F*\[1, 19\] = 3.4, *p*=0.08), as the placebo group increased by 200.5% (SD = 156.5), whereas the RBAC group decreased by 68.9% (SD = 160.2). The percent change in IL-2 from baseline to 90 days was significantly different (*F*\[1, 19\] = 6.7, *p*=0.02), as the placebo group increased by 76.5% (SD = 108.1), whereas the RBAC group decreased by 13.3% (SD = 37.8). The percent change in IFN-*γ* from baseline to 90 days was a statistical trend (*F*\[1, 19\] = 4.2, *p*=0.06), as the placebo group increased by 36.5% (SD = 128.9), whereas the RBAC group increased by 156% (SD = 131.8). The percent change in TNF RII from 45 to 90 days was a statistical trend (*F*\[1, 19\] = 3.6, *p* = 0.07), as the placebo group decreased by 22% (SD = 43.2), whereas the RBAC group increased by 7.1% (SD = 24.9).

4. Discussion {#sec4}
=============

The incidence and prevalence of NAFLD are rising worldwide with a paucity of available treatment approaches, aside from reducing liver fat content via weight loss \[20--23\]. Thus, it is important to explore promising dietary supplement or nutritional interventions such as RBAC.

The hepatic enzymes, i.e., AST, ALT, and ALP, constitute a classic group of tests to determine hepatocyte integrity, as elevated values suggest varying liver damage \[24\]. In the current study, ALP decreased in the RBAC group at 45 and 90 days, whereas in the placebo group, it increased, which is consistent with a rat study showing that ALT and AST were reduced by RBAC after GalN treatment \[10\]. The present finding is important, given that an increasing ALP level portends potential liver damage \[24\] and is related to steatosis and fibrosis \[25\].

The increases in percentages of eosinophils and monocytes at 90 days in the RBAC group suggest an immunomodulatory (or a short-term immunostimulatory increase) response, which parallels the effects that have been previously noted on various white blood cell counts or percentages in response to treatment with this polysaccharide \[26--28\]. In this case, a short-term mild inflammatory response could be beneficial to protect hepatocytes from damage, enable tissue damage restoration, and support the overall effort to achieve homeostasis, as opposed to chronic inflammation that would enhance liver injury and promote steatosis and cirrhosis \[29\]. Simultaneously, we observed nonsignificant decreases in both neutrophils (%) and NLR, which are clinically important. Neutrophils are the primary cells of the innate immune system, and their predominance is likely related to oxidative stress, initiation of matrix metalloproteinases, and a heightened proinflammatory response, e.g., activation of Th-17 molecules \[16, 30--33\]. In the current study in the RBAC group, as neutrophils decreased from baseline to 90 days, so did IL-17, which is consistent with other studies showing that neutrophils are important for activating IL-17 in the liver, particularly for fibrosis \[16, 34, 35\]. A higher NLR has been linked to poorer outcomes in NAFLD and NASH and is also predictive of mortality \[16, 36, 37\]. Additionally, GGT and 4-hydroxynonenal also decreased in the RBAC group, whereas both increased in the placebo group, however, nonsignificantly. GGT decreased to a value within the normal range (\<50 IU/L), which is clinically significant and of particular interest to NAFLD patients, given GGT\'s linear relationship to increasing levels of hepatobiliary disease and different neoplasms \[38--41\]. Additionally, both ALP and GGT decreased in the RBAC group, which is clinically significant as their movement together is used as an indicator of biliary obstruction \[42, 43\], giving more credibility to the current findings. Increased 4-hydroxynonenal is indicative of greater oxidative stress, and in addition to liver diseases, its production is implicated in the pathogenesis of cancer and neurodegenerative disorders \[44--47\]. Platelets are an acute phase reactant \[48, 49\], so the decrease observed in the RBAC group could possibly be an indicator of a beneficial effect, even though the values were within the normal range. Thus, the improvements in neutrophils, NLR, GGT, 4-hydroxynonenal, and platelets all suggest valuable clinical implications for this patient population.

IL-18 and the percentage of monocytes significantly increased from 45 to 90 days in the RBAC group compared to placebo. IL-18 is generally produced by monocytes and macrophages as an inflammatory response to either pathogens or stress \[50, 51\]. Additionally, the increase in IFN-*γ* in the RBAC group may be at least partially explained by the change in IL-18, as it has been shown that IL-18 initiates Th-1 polarization and stimulates NK cells, which together create large amounts of IFN-*γ* \[50, 52, 53\].

While IL-18 significantly increased from 45 to 90 days, the overall level from baseline to 90 days decreased in the RBAC group, however not significantly. The decrease in IL-18 is consistent with a previous rat study on RBAC and d-Ga1N-induced liver disease, which showed that RBAC suppressed a model of hepatitis by at least partially downregulating IL-18 \[9\]. Thus, the results of the current study suggest a complex interplay between monocytes, IL-18, and IFN-*γ* in response to our subjects taking RBAC.

4.1. Limitations {#sec4.1}
----------------

The results of the current study were likely limited due to several factors. We did not enroll only patients who had liver biopsies due to the difficulty of finding an adequate number of potential subjects willing to undergo this procedure, so the referring physician\'s diagnosis of NAFLD was based on a number of clinical factors that contain some error, e.g., body composition and liver enzyme tests. A homogenous sample of subjects related to disease stage was not included, as some subjects were newly diagnosed, whereas others had been diagnosed for several years. Thus, the results could have been affected by using subjects with a range of mild to severe disease. While subjects taking other polysaccharide dietary supplements and certain medications were excluded, we did not omit other agents, such as antioxidants, polyphenols, or other phytochemicals. Thus, those nutrients might have confounded the results. Diet was not evaluated in this study, particularly fats, which could have also confounded the results, even in a 90-day period. As fats, such as palmitic acid, which are common in the human diet, are used to create NAFLD-type models in animals \[54\], it would be important to know if total energy, macronutrient content, or other micronutrients contributed to the results in this study. Physical exercise also was not assessed in this study, and this variable could also have been a confounding factor, as regular exercise in mice proliferates IL-18 secretion \[55\]. The study included a relatively small sample size in a 90-day intervention period on a modest dose of RBAC (1 g/day). The decision to use 1 g/day was due in part to the results of our prior study in healthy adults \[15\], but patients with a complex disease such as NAFLD may require a higher dose to achieve more significant results.

5. Conclusions {#sec5}
==============

Conventional medicine has provided limited efficacious treatment for NAFLD patients. Currently, the only effective remedy for reducing fat in the liver is through weight loss with consistent hypocaloric eating. Nonetheless, compared to pharmacological treatments that offer minimal benefits, yet are associated with clear side effects, an efficacious dietary supplement would provide the cells with raw materials to support innate biochemical and physiological optimization and restoration. RBAC has historically conferred immunomodulatory benefits in humans, animals, and cells on a wide variety of outcome variables, e.g., NK and dendritic cells, IL-6, TNF-*α*, IFN-*γ*, and VEGF, to name only a few \[13, 15, 56, 57\]. Given our previous work in healthy adults showing that RBAC enhances NK cell cytotoxicity and improves the overall inflammatory profile according to a number of cytokines and growth factors \[15\], we chose to evaluate its effect on several biomarkers relevant to NAFLD.

In this study, RBAC caused no adverse effects, and no subject reported any complications with the intervention. Attrition was minimal, and compliance to the intervention was acceptable at both follow-ups. ALP, a hallmark liver enzyme, significantly improved in response to RBAC. The percentage of eosinophils and monocytes increased at the 90-day follow-up, suggestive of an immunomodulatory response, which is consistent with previous findings on RBAC. Platelets decreased in the RBAC group, which may be another important clinical improvement for this population, as possible modulation of an acute phase reactant. Although statistically nonsignificant, neutrophils, NLR, GGT, and 4-hydroxynoneal all improved in the RBAC group, which have important clinical implications for these patients. ALP and GGT both declined in response to RBAC, which is a clinically significant finding for hepatobiliary observation. IFN-*γ* increased from baseline to 90 days, while IL-18 increased from 45 to 90 days, in the RBAC group in what appears to be a complex relationship among these immune markers that has been documented previously. The overall decrease in IL-18 from baseline to 90 days is consistent with a previous animal study on RBAC.

No other statistically or clinically significant effects were noted in the biomarkers in response to RBAC. Nonetheless, combined with our prior findings on RBAC and those of others showing such potent immunomodulatory activity, the results of the present study support the use of this product for patients with NAFLD as a complement or alternative to conventional medical treatments. RBAC is an all-natural product with no documented side effects and has no known negative interactions with pharmaceuticals or other dietary supplements.

The next step in the evaluation of RBAC would be to extend the current study with perhaps a higher dose and a larger sample size for a longer intervention duration and utilize stricter inclusion criteria to enroll patients with liver biopsy to make the sample more homogenous. In addition, assessing NK cell function, given its relationship to monocytes and the Th-1 immune response, might shed further light on the effect of RBAC in this population. Given the encouraging findings in the current study, additional research is warranted to evaluate RBAC as a treatment option for patients with NAFLD, a complex disease that still has many mysteries related to its etiology.
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###### 

Sociodemographic characteristics of the sample.

  Variable                     Category              RBAC (*n* = 12)                       Placebo (*n* = 11)                    Statistic
  ---------------------------- --------------------- ------------------------------------- ------------------------------------- -----------------------------
  Age                          ---                   *M* = 58.1, SD = 15.2, *R* = 21, 75   *M* = 50.6, SD = 11.6, *R* = 25, 61   *t* = 1.3 (21), *p* = 0.20
  Gender                       Male                  9 (41%)                               13 (52%)                              *χ* ^2^ = 0.6 (1), *p*=0.45
  Female                       13 (59%)              12 (48%)                                                                    
  Race/Ethnicity               White, non-Hispanic   5 (42%)                               1 (9%)                                *χ* ^2^ = 5.9 (3), *p*=0.12
  Black, non-Hispanic          1 (8%)                ---                                                                         
  Hispanic                     4 (33%)               9 (82%)                                                                     
  Other                        2 (17%)               1 (9%)                                                                      
  Education                    Up to some college    4 (33%)                               4 (36%)                               *χ* ^2^ = 0.2 (2), *p*=0.93
  College graduate             3 (25%)               2 (18%)                                                                     
  Master\'s degree or higher   5 (42%)               5 (46%)                                                                     
  Marital status               Never married         3 (25%)                               4 (36%)                               *χ* ^2^ = 2.4 (2), *p*=0.31
  Married                      7 (58%)               3 (28%)                                                                     
  Divorced                     2 (17%)               4 (36%)                                                                     

*M* = mean, SD = standard deviation, and *R* = range.

###### 

Liver enzymes, kidney function, lipids, and oxidative stress markers at baseline and 45 and 90 days.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Measure                           Reference range                                                              Time                             RBAC                         Placebo
  --------------------------------- ---------------------------------------------------------------------------- -------------------------------- ---------------------------- --------------------------
  ALP (U/L)^*∗*^                    Male (40--129)\                                                              Baseline                         86 ± 37.6 (47, 172)          86.1 ± 31.8 (44, 141)
                                    Female (35--104)                                                                                                                           

  45 days                           81.2 ± 27.5 (45, 130)                                                        91.8 ± 39.8 (43, 168)                                         

  90 days                           80 ± 25.4 (50, 140)                                                          96.8 ± 38.1 (46, 159)                                         

  ALT (U/L)                         Male (0--40)\                                                                Baseline                         39.4 ± 21.9 (12, 74)         57.8 ± 37 (13, 114)
                                    Female (0--35)                                                                                                                             

  45 days                           35.9 ± 22.9 (11, 83)                                                         59 ± 42.7 (16, 140)                                           

  90 days                           38.6 ± 30.5 (13, 118)                                                        55.4 ± 49 (13, 165)                                           

  AST (U/L)                         Male (0--43)\                                                                Baseline                         28.8 ± 10.3 (17, 48)         42.6 ± 20.2 (14, 92)
                                    Female (0--32)                                                                                                                             

  45 days                           29.2 ± 13.4 (15, 56)                                                         43.3 ± 22.1 (20, 83)                                          

  90 days                           30.4 ± 17.9 (17, 81)                                                         44.4 ± 30.3 (19, 120)                                         

  AST/ALT ratio                     Male (\<1)\                                                                  Baseline                         0.86 ± 0.31 (0.58, 1.44)     0.9 ± 0.34 (0.48, 1.39)
                                    Female (\<1)                                                                                                                               

  45 days                           0.95 ± 0.33 (0.58, 1.54)                                                     0.9 ± 0.36 (0.56, 1.65)                                       

  90 days                           0.92 ± 0.32 (0.57, 1.67)                                                     1.02 ± 0.42 (0.52, 1.72)                                      

  *γ*-glutamyl transferase (IU/L)   0--51                                                                        Baseline                         67.5 ± 80.6 (13, 304)        78.6 ± 87.7 (8, 300)

  45 days                           51.4 ± 49.3 (15, 182)                                                        83.1 ± 74.1 (14, 248)                                         

  90 days                           46.7 ± 38.1 (13, 126)                                                        98.2 ± 94.6 (15, 291)                                         

  Albumin (g/dL)                    3.5--5.2                                                                     Baseline                         4.6 ± 0.3 (4.1, 4.9)         4.5 ± 0.4 (3.6, 4.9)

  45 days                           4.5 ± 0.2 (4.3, 4.7)                                                         4.5 ± 0.5 (3.3, 5.2)                                          

  90 days                           4.5 ± 0.3 (4, 4.9)                                                           4.6 ± 0.5 (3.5, 5)                                            

  Non-HDL cholesterol (mg/dL)       \<100 for healthy subjects; \<80 for subjects with coronary artery disease   Baseline                         142.5 ± 26.7 (81, 184)       146.7 ± 68.8 (36, 275)

  45 days                           147.9 ± 33.6 (103, 214)                                                      143.3 ± 65.7 (33, 247)                                        

  90 days                           142.8 ± 28.1 (96, 206)                                                       144.6 ± 55.7 (37, 220)                                        

  4-Hydroxynonenal (*μ*g/mL)        None                                                                         Baseline                         121.1 ± 163.6 (6.2, 588.1)   144.5 ± 203 (5.7, 636.9)

  45 days                           112.7 ± 150.8 (13.3, 534.7)                                                  252.4 ± 367.4 (5.9, 1035.7)                                   

  90 days                           75.9 ± 50.8 (19.4, 157.7)                                                    911.3 ± 2,258.3 (7.9, 6,485.6)                                
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Values are mean ± standard deviation (minimum, maximum). ALP, alkaline phosphatase; ALT, alanine transaminase; AST, aspartate transaminase; HDL, high-density lipoprotein. ^*∗*^Percent change difference (*p* \< 0.05) from baseline to 90 days.

###### 

White blood cell subsets and platelets at baseline and 45 and 90 days.

  Measure                               Reference range            Time                      RBAC                      Placebo
  ------------------------------------- -------------------------- ------------------------- ------------------------- -------------------------
  White blood cells (10^3^/*μ*L)^*∗*^   4.3--10.3                  Baseline                  6.7 ± 2.7 (3.6, 13.8)     5.5 ± 1.1 (2.5, 6.4)
  45 days                               6.5 ± 2.5 (3.8, 12)        5.8 ± 1.5 (4.2, 9)                                  
  90 days                               6.7 ± 2.8 (3.4, 13.4)      6 ± 1.6 (2.8, 8.4)                                  
  Neutrophils (%)                       41--73                     Baseline                  53.1 ± 9.2 (37.7, 65.7)   56.7 ± 6.1 (45, 67.6)
  45 days                               50.8 ± 10.2 (25.8, 64.5)   56.4 ± 5.9 (45.8, 65.3)                             
  90 days                               48.5 ± 10.6 (25.5, 66.9)   56.6 ± 6.1 (47.6, 64.8)                             
  Lymphocytes (%)                       19.4--44.9                 Baseline                  36.8 ± 7.5 (26, 51.2)     32.7 ± 5.7 (22.9, 42.6)
  45 days                               37.9 ± 9.6 (23.6, 61.8)    32.8 ± 6.5 (20.2, 42)                               
  90 days                               38.6 ± 9.6 (22.2, 60.1)    32.4 ± 4.9 (29.4, 39)                               
  Neutrophil/lymphocyte ratio           None                       Baseline                  1.5 ± 0.6 (0.7, 2.5)      1.8 ± 0.5 (1.1, 2.5)
  45 days                               1.5 ± 0.6 (0.4, 2.7)       1.8 ± 0.6 (1.1, 3.0)                                
  90 days                               1.4 ± 0.7 (0.4, 3.0)       1.8 ± 0.4 (1.2, 2.3)                                
  Monocytes (%)^+^                      5.1--10.9                  Baseline                  7.3 ± 2.1 (3.5, 11.8)     7.3 ± 4 (3.6, 18.5)
  45 days                               7.8 ± 1.2 (5.9, 10.1)      8.1 ± 3.3 (5.5, 16.5)                               
  90 days                               9.1 ± 1.3 (6.9, 11.3)      8.1 ± 4.4 (4.5, 19.4)                               
  Eosinophils (%)\^^*∗*^                0.9--6.0                   Baseline                  2.5 ± 1.3 (1.2, 4.9)      2.9 ± 1.4 (1.1, 5.5)
  45 days                               3 ± 1.2 (2.1, 5.5)         2.2 ± 1.1 (0.5, 4.1)                                
  90 days                               3.3 ± 1.5 (1.6, 6)         2.2 ± 1.2 (0.8, 4.4)                                
  Platelets (10^3^/*μ*L)^*∗*^           156--373                   Baseline                  254.8 ± 90.5 (180, 511)   196.9 ± 61.9 (81, 292)
  45 days                               225.6 ± 46.7 (170, 311)    194.3 ± 65.3 (55, 267)                              
  90 days                               229.5 ± 51.8 (176, 351)    210.4 ± 91.6 (65, 398)                              

Values are mean ± standard deviation (minimum, maximum). ^*∗*^Percent change difference (*p* \< 0.05) from baseline to 90 days; ^+^percent change difference (*p* \< 0.05) from 45 days to 90 days; \^percent change difference (*p* \< 0.05) from baseline to 45 days.

###### 

Cytokines and growth factors at baseline and 45 and 90 days.

  Measure             Reference range                   Time                                 RBAC                           Placebo
  ------------------- --------------------------------- ------------------------------------ ------------------------------ ---------------------------------
  IL-6 (pg/mL)        0.6--2.8                          Baseline                             1.4 ± 1.4 (0.01, 4.8)          0.7 ± 0.9 (0.01, 2.1)
  45 days             1.4 ± 0.9 (0.01, 2.7)             2.8 ± 1.7 (0.01, 5.2)                                               
  90 days             1.7 ± 0.9 (0.09, 3.3)             1.7 ± 1.3 (0.01, 4.2)                                               
  IL-18 (pg/mL)^+^    36.1--257.8                       Baseline                             446.1 ± 876 (64.5, 3,221)      256.4 ± 106.8 (86.6, 430.2)
  45 days             196.3 ± 64.7 (49.6, 284)          371 ± 176.5 (83.8, 597.1)                                           
  90 days             221.3 ± 44.9 (153.5, 300.2)       263.3 ± 116.2 (75.7, 4.9.5)                                         
  IFN-*γ* (pg/mL)     0--3.0                            Baseline                             1.3 ± 1.5 (0.01, 5.1)          2.3 ± 2.5 (0.01, 7.8)
  45 days             2.5 ± 1.9 (0.01, 7.4)             2.4 ± 0.9 (1.1, 4.2)                                                
  90 days             2.3 ± 1.5 (0.01, 4.9)             1.9 ± 1.8 (0.01, 4.9)                                               
  IL-2 (pg/mL)^*∗*^   1.6--8.3                          Baseline                             8.4 ± 3.3 (4.2, 13.2)          7.8 ± 6.5 (0.01, 21.2)
  45 days             7.5 ± 3.5 (0.01, 11.7)            7.6 ± 3.1 (4.9, 14.1)                                               
  90 days             6.5 ± 4 (3.8, 18.2)               8.2 ± 3.8 (4.5, 16.4)                                               
  TNF RII (pg/mL)     714.4--1,145.5                    Baseline                             136.2 ± 443.2 (369.7, 1,940)   1259.9 ± 709.5 (391.9, 2,749.3)
  45 days             991.1 ± 277.5 (624.1, 1,530.6)    3449.2 ± 7,339.7 (596.1, 22,998.6)                                  
  90 days             1029.8 ± 275.5 (649.1, 1,564.1)   950.3 ± 506.4 (329.9, 1,753.1)                                      
  IL-17 (pg/mL)       1.4--5.0                          Baseline                             7.6 ± 8.2 (3.3, 33.4)          6.3 ± 3.7 (3.6, 16.9)
  45 days             7.4 ± 6.2 (3.5, 25.8)             7.8 ± 4.7 (2.2, 16.7)                                               
  90 days             5.5 ± 3.7 (0.1, 10.9)             4.9 ± 3.3 (1.1, 10.2)                                               

Values are mean ± standard deviation (minimum, maximum). IL, interleukin; IFN, interferon; TNF, tumor necrosis factor; ^*∗*^percent change difference (*p* \< 0.05) from baseline to 90 days; ^+^percent change difference (*p* \< 0.05) from 45 days to 90 days.
